U.S. pharmaceuticals giant Eli Lilly & Co has hit another obstacle in its quest for copyright protection in China for the drug Prozac. The Beijing Municipal People's High Court last week upheld a verdict by a lower-level Beijing court not to grant the company so-called administrative protection for the antidepressant drug.